Latest Industry Trends & News

Recently Added

10/11/2018
orthopedicpress release
Market Scope Announces Launch of New Website and Entry into Orthopedics

Market Scope, an industry leader for ophthalmic market research, announced today the launch of its new website and the firm’s entry into orthopedics, its second medical vertical. The new Market-Sco...

12/14/2018
newsletterorthopedic
Rejoint Completes YourKnee Testing

Rejoint announced the completion of mechanical testing for its YourKnee implant on Nov. 30. YourKnee is a cobalt chrome 3D-printed system for TKA that uses AI to custom-fit each patient. The first ...

12/14/2018
newsletterorthopedic
Zimmer Stimulator Recall

The US FDA announced on Nov. 27 that Zimmer Biomet initiated a Class I recall of its OsteoGen Implantable Bone Growth Stimulator, SpF Plus-Mini Implantable Fusion Stimulator, and SpF-XL Implantable...

12/14/2018
newsletterorthopedic
Exparel From Pacira Reduces Opioid Use, Length of Stay, and Cost of TKA

New Jersey-based Pacira Pharmaceuticals Inc. announced Nov. 27 that results from a recent study showed Exparel’s (bupivacaine liposomal injectable suspension) success in managing TKA pain. The stud...

12/14/2018
newsletterorthopedic
WishBone Medical Acquires Response Ortho

Indiana-based WishBone Medical Inc. announced Nov. 28 that it acquired Response Ortho. Response Ortho, located in Turkey, produces external and internal fixation and deformity products for pediatri...

12/14/2018
newsletterorthopedic
Sasso Wins $112M From Case Against Medtronic

Rick Sasso, MD, won $112 million in damages from Medtronic, the Indianapolis Business Journal announced Nov. 30. The legal battle lasted five years and culminated in a unanimous verdict from a six-...

12/14/2018
breakingophthalmic
Akorn Looks for New CEO after Latest Court Loss over Fresenius Deal

Akorn Pharmaceuticals announced Dec. 7 that it was searching for a new CEO following another legal defeat in the company’s fight to salvage its deal with Fresenius Kabi. The Supreme Court of the St...

12/14/2018
breakingophthalmic
Atia Vision Raises $10 Million in Series C to Advance Accommodating IOL

Atia Vision of Campbell, California, reported Dec. 10 that it closed the second tranche of a Series C preferred stock financing Nov. 9, raising a total of $10 million. The company is developing a m...

12/14/2018
breakingophthalmic
OCTANe Names Mazzo Board Chair

Orange Country Technology Alliance’s (OCTANe) has named James Mazzo as its chair. Mazzo will assume the post for two years beginning Jan. 1. Mazzo is the global president of ophthalmic devices at C...

12/14/2018
breakingophthalmic
Galimedix Therapeutics Names Hermann Russ Chief Scientific Officer

Galimedix Therapeutics has named Hermann Russ, MD, PhD, as its chief scientific officer, the company announced Dec. 11. Russ invented the use of the company’s lead molecule GAL-101/MRZ-99030 for th...

12/14/2018
breakingophthalmic
Alembic Receives US Approval for Generic Olopatadine Formulation

India’s Alembic Pharmaceuticals announced Dec. 10 that it gained US FDA approval for its Olopatadine Hydrochloride Ophthalmic Solution 0.1% for the treatment of the signs and symptoms of allergic c...

12/14/2018
breakingophthalmic
Alimera Sciences Names Rick Eiswirth as CEO

Alimera Sciences announced Nov. 29 that Rick Eiswirth will take over Jan. 2 as chief executive officer. Eiswirth, who has served as the company’s president for three years, also will join the board...

Past News Stories

12/14/2018
breakingophthalmic
Oncobiologics Becomes Outlook Therapeutics

Oncobiologics has changed its name to Outlook Therapeutics, the company announced Dec. 5. The company’s lead product candidate, ONS-5010, is a proprietary ophthalmic bevacizumab product candidate f...

12/14/2018
breakingophthalmic
Criminal Case Against Mazzo Dropped

Federal prosecutors dropped their criminal charges against James Mazzo after the ophthalmic industry veteran agreed to a deal with the SEC in November. Mazzo agreed to a pay a $1.5 million civil pe...

12/14/2018
breakingophthalmic
AGTC Drops Gene Therapy Program for X-Linked Retinoschisis

AGTC will drop its gene therapy program for X-linked retinoschisis (XLRS) following interim six-month data from a Phase I/II study, the company announced Dec. 12. The trial has been investigating r...

12/12/2018
ophthalmicpress release
Global Dry Eye Products Market to Total $6.2 Billion in 2023

Providers of dry eye therapies can expect to see healthy growth in revenues overall in the next five years as people suffering from dry eye increasingly seek treatment. Market Scope looks for manuf...

12/10/2018
ophthalmicpress release
Ophthalmic Investment Funds Led by Retinal Gene Therapy Developers

Transactions totaled $3.6 billion in 2017 and $1.7 billion in the first nine months of 2018. Ophthalmology remains one of the most active areas of medical technology investment, attracting monies f...

12/10/2018
newsletterorthopedic
November/December News Briefs

MRI Interventions Collaborates With Clinical Laserthermia Systems to Pair Navigation With Ablation California-based MRI Interventions Inc. and Sweden-based Clinical Laserthermia Systems AB (CLS) an...

12/10/2018
newsletterorthopedic
Q3-2018 Earnings Report

Publicly-owned company results are in for Q3-2018, and overall orthopedic revenues, including Market Scope estimates for private companies, increased 2.3 percent to $9.3 billion from the same quart...

12/10/2018
newsletterorthopedic
Monthly Orthopedic Fundraising

The overall value of the orthopedic market increases when companies obtain money from outside sources such as fundraising or grants. The goal of this feature is to track the influx of money in each...

12/10/2018
newsletterorthopedic
Novartis Acquires Gene Therapy Start-up for $8.7B

Novartis took a giant and costly step in April to acquire AveXis, thereby laying claim to a promising gene therapy for the treatment of spinal muscular atrophy (SMA). The gene therapy technology al...

12/10/2018
newsletterorthopedic
White House Targets Health Care Costs

President Donald Trump and his administration announced on Oct. 25 new measures to bring down health care costs. US health officials announced in August that privately administered Medicare plans, ...

12/10/2018
newsletterorthopedic
Orthopedic US 510(k) Clearances

Thirty-nine orthopedic devices and biologics received FDA 510(k) clearance between October 15 and November 14, which represents a greater than 20-percent reduction from the same period in 2017. Fif...

12/10/2018
newsletterorthopedic
Regenerative Treatments for DDD

Degenerative disc disease (DDD) is a complex disorder that contributes to low back pain in many patients. More than three-quarters of the population experiences low back pain at some point. DDD typ...

Want to Read the Full Article?

Register A Corporate Account

A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.

Select one or more
Select one or more